Effect of Anti-IgE in Non-Allergic Asthma

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Johns Hopkins University
Study ID
NCT00162773
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • omalizumab — DRUG
    150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE.
  • Placebo — OTHER
    150-375 milligrams depending on body weight and serum IgE.

Study Details

The purpose of this study is to find out if omalizumab is effective in treating non-allergic asthma. The US Food and Drug Administration has approved the use of omalizumab to treat moderate to severe allergic asthma.

Key Dates

Start date
Apr 30, 2005
Status verified
Jul 2017
Primary completion
Sep 30, 2009
Completion
Sep 30, 2009

Study Design

Enrollment
29 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo
    water injection
  • Experimental: Omalizumab
    Other Names: Xolair 150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE.

Primary Outcome Measure

Changes in Free Serum IgE Levels From Baseline [ Time Frame: baseline to 2 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Johns Hopkins Asthma and Allergy CenterBaltimoreMaryland21224-

Find similar trials in Baltimore, MD

By condition
Asthma
By specialty
PulmonologyLung disease
By research site
Johns Hopkins Asthma and Allergy Center· Baltimore, MD

Related Studies